US Patent

US9828606 — Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA

Composition of Matter · Assigned to Dicerna Pharmaceuticals Inc · Expires 2034-12-26 · 9y remaining

Vulnerability score 4/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects methods and compositions that use double-stranded RNA to specifically inhibit the enzyme Glycolate Oxidase (HAO1).

USPTO Abstract

This invention relates to compounds, compositions, and methods useful for reducing Glycolate Oxidase (HAO1) target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.

Drugs covered by this patent

lumasiran-sodium (LUMASIRAN SODIUM)

Patent Metadata

Patent number: US9828606
Jurisdiction: US
Classification: Composition of Matter
Expires: 2034-12-26
Drug substance claim: Yes
Drug product claim: Yes
Assignee: Dicerna Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.